Lista de obras -

Adherence-dependent shifts in the patterns of beta-amyloid peptides secreted by human mononuclear phagocytes.

artículo científico publicado en 2008

Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.

artículo científico publicado en 2007

Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease

artículo científico publicado en 2004

Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

scientific article published on 07 August 2006

Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

artículo científico publicado en 2003

Blood-based neurochemical diagnosis of vascular dementia: a pilot study.

artículo científico publicado en 2007

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

artículo científico publicado en 2006

CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.

artículo científico publicado en 2011

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

scholarly article by Mirko Bibl et al published September 2004 in Electrophoresis

Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review

artículo científico publicado en 2008

Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.

artículo científico publicado en 2010

Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

artículo científico publicado en 2010

Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

artículo científico publicado en 2009

Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease

scientific article published on 06 January 2011

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

scientific article published on 01 February 2006

Electrophoretic separation of amyloid beta peptides in plasma.

artículo científico publicado en 2004

Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases.

artículo científico publicado en 2004

International quality control survey of neurochemical dementia diagnostics.

artículo científico publicado en 2006

Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form

artículo científico publicado en 2009

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

artículo científico publicado en 2007

Plasma amyloid-beta peptides in acute cerebral ischemia: a pilot study.

artículo científico publicado en 2012

Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies

artículo científico publicado en 2007

Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature

artículo científico publicado en 2004

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies

artículo científico publicado en 2005

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

artículo científico publicado en 2006

Lista de obras de

Adherence-dependent shifts in the patterns of beta-amyloid peptides secreted by human mononuclear phagocytes.

Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.

Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease

Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Blood-based neurochemical diagnosis of vascular dementia: a pilot study.

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review

Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.

Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

Electrophoretic separation of amyloid beta peptides in plasma.

Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases.

International quality control survey of neurochemical dementia diagnostics.

Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

Plasma amyloid-beta peptides in acute cerebral ischemia: a pilot study.

Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies

Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.